MAPT and Alzheimer disease: Entorhinal cortex sections (× 12 per brain sample) from brains presenting mild (Braak stage II, n = 3), moderate (Braak stage IV, n = 3) or severe (Braak stage VI, n = 4) AD pathology, or from FTLD-tau brains (n = 2) or control brains (n = 4), were immunostained with the tau-pT123 and tau-pT427 antibodies.